NantHealth & NantOmics Present Four Research Papers Demonstrating Advancements in Cancer Diagnostics with NantHealth’s GPS ...
29 October 2018 - 11:00PM
Business Wire
NantHealth’s Liquid GPS™ technology shows
promise in the monitoring of key biomarkers in metastatic
colorectal cancer
Significant developments in cancer research were presented by
NantHealth (NASDAQ: NH) and NantOmics at the ESMO conference in
Munich, Germany this week. NantHealth, a leader in breakthrough
cancer research and solutions to improve patient care and lower
healthcare costs, in conjunction with NantOmics, a leader in
molecular diagnostic testing, conducted one oral presentation and
four papers, including a few demonstrating the promise of the
company’s Liquid GPS™, a blood-based molecular test that provides
oncologists with a powerful tool for non-invasive tumor profiling
and quantitative monitoring of treatment response. ESMO is the
world’s second largest cancer symposium where researchers and
clinicians come together to study the latest breakthroughs in
treatment.
“We continue to be on the cutting edge of cancer research and
that, coupled with the advancements we’re making in all areas of
cancer diagnostics, treatment plans and provider solutions, are all
important steps in supporting physicians and patients,” said Dr.
Sandeep Reddy, Chief Medical Officer, NantHealth. “Our researchers
and scientists are working very hard to tackle some of the toughest
challenges in cancer research and sharing them as quickly as
possible. Our Liquid GPS™ tumor profiling is dramatically changing
the way that physicians identify and treat different types of
cancer.”
The oral presentation, Gene mutation status in circulating tumor
DNA (ctDNA) and first-line FOLFOXIRI plus bevacizumab (bev) in
metastatic colorectal cancer (mCRC) harboring RAS mutation,
authored by Y. Sunakawa, et al, includes investigational data
suggesting that circulating DNA markers may predict outcomes in
mCRC and can guide treatment decisions for these patients.
Additional papers were reviewed showing breakthroughs in immune
oncology, including:
Title: Differential expression of PD-L1 and immune
biomarkers by age: Decreased expression in pediatric/AYA patients
with advanced cancerAuthor: Dr. Omid Hamid, et
alDescription: Whole exome and RNA sequencing of 1,467
patients highlights younger patients (age < 24) with advanced
cancer appear to have lower levels of CTLA4 and PD-L1
expression.Key Takeaway: Immune checkpoint drugs have not
yet been approved in pediatric and adolescent/young adult patients.
Large dataset results show it may be necessary to employ new
combinations to be used in younger patients such as Nant’s Cancer
Vaccine, immunotherapy that combines the delivery of metronomic,
low-dose chemotherapy and radiation therapy with natural killer
(NK) cell-based technology to enhance patient’s immune system
response against cancer cells.
Title: PD-L1 expression is strongly associated with
TIGIT, FOXP3 and LAG3 across advanced cancers, but not OX40, TIM3
and IDOAuthor: Dr. Sumanta K. Pal, et alDescription:
RNA sequencing reveals immune checkpoint gene expression was not
significantly different in TMB high versus low groups. In patients
demonstrating the highest PD-L1 expression, higher expression of
CTLA4, TIGIT, FOXP3 and LAG3 were also observed.Key
Takeaway: While researchers are focused on TMB as a more
promising biomarker for Immuno-Oncology (IO) therapy than PDL1,
this research shows PDL1 may be a marker of generalized tumor
inflammation and could be the reason those tumors respond to IO
drugs.
Title: Predicting survival benefit of capecitabine plus
cisplatin in patients with metastatic gastric cancer using
quantitative proteomicsAuthor: D. Yan, et
alDescription: Targeted proteomic analysis of metabolic
enzymes required for intracellular activation of the
chemotherapeutic drug capecitabine identifies specific enzymes and
expression cutoffs which are significantly associated with extended
survival in metastatic gastric cancer patients given this drug
regimen.Key Takeaway: Clinical tissue analysis of specific
proteomic biomarkers could be used to better personalize the usage
of chemotherapeutic agents.
Title: Development and validation of neuroendocrine tumor
marker panel in small biopsies using multiplexed mass
spectrometryAuthor: S. Thyparambil, et alDescription:
Immunohistochemical analysis of neuroendocrine tumor markers is
performed on only a small subset of cancer. In spite of the
approval of several new agents with specific activity against
neuroendocrine tumors. A multiplexed clinical tissue proteomics
assay was developed to add analysis of neuroendocrine markers into
a larger diagnostic panel in order to better identify candidates
for neuroendocrine specific therapy.Key Takeaway: A three
protein targeted proteomics assay can identify neuroendocrine
tumors with high sensitivity and specificity. The expanded use of
this technology may efficiently identify patients for optimal
therapy.
About NantHealth
NantHealth, Inc., a member of the NantWorks ecosystem of
companies, uses personalized data to improve patient care and lower
healthcare costs. NantHealth leads the way in providing oncologists
with unprecedented insights that enable cancer treatment tailored
to the individual characteristics of each patient. NantHealth
solutions reduce the cost of care by connecting patient data and
streamlining the accurate collection and sharing of that
data--starting from a patient’s bedside, extending to payers and
providers. NantHealth improves clinical decision support,
eliminates unwarranted care and seeks to enhance. For more
information please visit www.nanthealth.com.
About NantOmics
NantOmics, a member of the NantWorks ecosystem of companies,
delivers molecular analysis capabilities with the intent of
providing actionable intelligence and molecularly driven decision
support for cancer patients and their providers at the point of
care. NantOmics is the first molecular analysis company to pioneer
an integrated approach to unearthing the genomic and proteomic
variances that initiate and drive cancer, by analyzing both normal
and tumor cells from the same patient and following identified
variances through from DNA to RNA to protein to drug. NantOmics has
a highly scalable cloud-based infrastructure capable of storing and
processing thousands of genomes a day, computing genomic variances
in near real-time, and correlating proteomic pathway analysis with
quantitative multiplexed protein expression analysis from the same
micro-dissected tumor sample used for genomic analysis. For more
information please visit www.nantomics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181029005206/en/
NANTJen Hodson, 562-397-3639jhodson@nantworks.com
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jun 2024 to Jul 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jul 2023 to Jul 2024